心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Diabetes：高血压遗传易感性增加2型糖尿病人群CVD风险

2012-07-31 张一宸 医学论坛网

高血压心血管疾病风险2型糖尿病
关注

　　高血压和2型糖尿病（T2D）常常并存，且二者均是心血管疾病（CVD）的主要危险因素。7月24日，《糖尿病》（Diabetes）杂志在线发表了一项研究旨在分析T2D患者高血压遗传易感性与CVD的关系，结果表明T2D个体高血压遗传易感性高增加CVD风险。 　　护士健康研究和健康专业人员随访研究共涉及1005例男性和1229例女性T2D患者，其中732例发生CVD。根据29个以确定的血压相关基因变

遗传易感性

　　高血压和2型糖尿病（T2D）常常并存，且二者均是心血管疾病（CVD）的主要危险因素。7月24日，《糖尿病》（Diabetes）杂志在线发表了一项研究旨在分析T2D患者高血压遗传易感性与CVD的关系，结果表明T2D个体高血压遗传易感性高增加CVD风险。

　　护士健康研究和健康专业人员随访研究共涉及1005例男性和1229例女性T2D患者，其中732例发生CVD。根据29个以确定的血压相关基因变异体进行这些人群的遗传易感性评分。研究结果如下，易感性评分与男性和女性CVD风险均相关。在复合结果中，每增加一个额外高血压等位基因可使CVD风险增加6% [危险比（OR）1.06，95% CI为1.03–1.10]。与普通人相比，这种遗传相关性在T2D患者中更为显著（每1遗传评分危险比1.22对1.10）。

　　链接：Qi Q, Forman JP, Jensen MK, Flint A, Curhan GC, Rimm EB, Hu FB, Qi L.Genetic Predisposition to High Blood Pressure Associates With Cardiovascular Complications Among Patients With Type 2 Diabetes.Diabetes,2012 Jul 24



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-04-17 ms5439512287675881

    #BET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-06-19 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-02-11 木头人513

    #Diabetes#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2013-06-08 qingrejiedu

    #CVD风险#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-11 mustafa

    This is crtysal clear. Thanks for taking the time!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-02 kcb071

    #遗传易感性#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1759168, encodeId=354f1e591684a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 17 13:51:00 CST 2013, time=2013-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636536, encodeId=577316365363d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jun 19 12:51:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900977, encodeId=f73019009e7d7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 11 15:51:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970422, encodeId=9a4219e042249, content=<a href='/topic/show?id=087e55169e' target=_blank style='color:#2F92EE;'>#CVD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5516, encryptionId=087e55169e, topicName=CVD风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 08 16:51:00 CST 2013, time=2013-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4606, encodeId=f9e546067f, content=This is crtysal clear. Thanks for taking the time!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=mustafa, createdTime=Sat Aug 11 01:20:00 CST 2012, time=2012-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454694, encodeId=f843145469480, content=<a href='/topic/show?id=7467951e7b1' target=_blank style='color:#2F92EE;'>#遗传易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95177, encryptionId=7467951e7b1, topicName=遗传易感性)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a435588697, createdName=kcb071, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460497, encodeId=d585146049e77, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-02 FukaiBao

    #易感性#

    0

相关资讯

维吾尔族与汉族老年高血压患者靶器官损害比较

　　近日，新疆医科大学第一附属医院心功能科、新疆医科大学第一附属医院干部病房的孙焕文、张颖等共同发表论文，旨在探讨新疆维吾尔族与汉族老年高血压患者靶器官损害的临床特点。研究指出，维吾尔族老年高血压患者血压偏高，易于合并冠心病和(或)糖尿病，发生代谢紊乱、房性心律失常、心肌缺血及颈动脉斑块形成等靶器官损害的比率高于汉族，同时心率变异性减低。该论文发表于2012年第14卷第3期《中华老年心脑血管病杂志

NDT：肾小球高滤过率随着糖尿病和高血压前期的增高而增加

　　该研究纳入了日本爱知县接受健康检查的99140名年龄20至89岁的对象。比较了各个时期糖尿病前期（FBS<100, 100–109, 110–125 and ≥126 mg/dl,分别表示无糖尿病前期，第1阶段糖尿病前期，第2阶段糖尿病前期和糖尿病）以及各个时期高血压前期（BP<120/80，120-129/80-84，130-139/85-89和≥140/90 mmHg，分别表示

天津社区老年脑卒中患者现状调查

　　近日，天津市环湖医院神经内科和天津市和平区白楼医院的吉凤，刘首峰，王惠等共同发表论文，旨在探讨社区脑卒中患者健康状况及脑卒中二级预防情况。研究指出，天津社区脑卒中患者中，缺血性脑卒中患者占绝大多数，高血压、糖尿病、冠心病和高脂血症患病率较高。通过规律用药，高血压、糖尿病控制较好，但饮食控盐较差。缺血性脑卒中二级预防中，抗血小板药物及他汀类药物应用率较低，还需要社会和医疗机构的宣教，提高患者健康

CKD血压管理 高效达标 心肾获益

　　美国国家肾病基金会（NKF）是致力于肾病和泌尿系统疾病的预防、治疗的非赢利健康组织，该组织同时管理肾脏病/透析临床实践指南（KDOQI）和改善全球肾脏病预后组织（KDIGO）指南。而鉴于高血压管理在肾科疾病中的重要性，KDIGO即将发布该组织的全球第一个肾科高血压指南。2012年5月9-13日在美国华盛顿召开的NKF春季临床会议也着力推广慢性肾脏病诊断与治疗的最新理念和进展，并提出了慢性肾脏病

高血压伴餐后高血糖老年炎性反应严重

　　近日，山西医科大学第二医院心内科的王瑞英、王蕊、郭琼等共同发表论文，旨在观察高血压伴餐后高血糖患者炎性因子水平及阿卡波糖的干预效应。研究指出，老年高血压伴餐后高血糖患者炎性反应较单纯高血压者严重，阿卡波糖可减轻炎性反应，延缓动脉粥样硬化进程。该论文发表于2012年第14卷第3期《中华老年心脑血管病杂志》上。 　　研究人员选择1级老年单纯收缩期高血压患者208例，根据是否伴餐后高血糖，将患者分

WHO发布非传染病重要统计数据

　　2012年5月16日,日内瓦 :5月16日发布的《2012年世界卫生统计》报告着重突出了日益严重的非传染性疾病负担问题。 　　根据这份报告，全球三分之一成年人患有高血压，这种病症的死亡人数约达中风和心脏病所导致的总死亡人数的一半。十分之一成年人患有糖尿病。 　　“这份报告进一步证明引发心脏病和其它慢性病的症状急剧增加，特别是在低收入和中等收入国家，”世卫组织总干事陈冯富珍博士说。